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ABSTRACT
Breast cancer is the disease with the highest impact on global health, being 
metastasis the main cause of death. To metastasize, carcinoma cells must reactivate 
a latent program called epithelial-mesenchymal transition (EMT), through which 
epithelial cancer cells acquire mesenchymal-like traits.
Glypican-3 (GPC3), a proteoglycan involved in the regulation of proliferation 
and survival, has been associated with cancer. In this study we observed that 
the expression of GPC3 is opposite to the invasive/metastatic ability of Hs578T, 
MDA-MB231, ZR-75-1 and MCF-7 human breast cancer cell lines. GPC3 silencing 
activated growth, cell death resistance, migration, and invasive/metastatic capacity 
of MCF-7 cancer cells, while GPC3 overexpression inhibited these properties 
in MDA-MB231 tumor cell line. Moreover, silencing of GPC3 deepened the MCF-7 
breast cancer cells mesenchymal characteristics, decreasing the expression of the 
epithelial marker E-Cadherin. On the other side, GPC3 overexpression induced the 
mesenchymal-epithelial transition (MET) of MDA-MB231 breast cancer cells, which 
re-expressed E-Cadherin and reduced the expression of vimentin and N-Cadherin. 
While GPC3 inhibited the canonical Wnt/β-Catenin pathway in the breast cancer cells, 
this inhibition did not have effect on E-Cadherin expression. We demonstrated that the 
transcriptional repressor of E-Cadherin - ZEB1 - is upregulated in GPC3 silenced MCF-7 
cells, while it is downregulated when GPC3 was overexpressed in MDA-MB231 cells. 
We presented experimental evidences showing that GPC3 induces the E-Cadherin 
re-expression in MDA-MB231 cells through the downregulation of ZEB1.
Our data indicate that GPC3 is an important regulator of EMT in breast cancer, 
and a potential target for procedures against breast cancer metastasis.
INTRODUCTION
Breast cancer is the leading cause of female 
mortality due to malignant diseases worldwide [1]. 
Despite recent major advances in the understanding 
of the mechanisms of breast cancer progression and 
in the development of novel therapeutic modalities, 
metastatic disease still remains the most critical 
condition limiting patient survival [2]. The chance of 
five year survival following diagnosis falls from >90% 
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for localized disease to <20% once metastasis has 
occurred.
Metastasis is defined as the formation of 
progressively growing secondary tumor foci at sites 
discontinuous from the primary lesion. To metastasize, 
carcinoma cells must reactivate a latent embryonic 
program called epithelial-mesenchymal transition 
(EMT) [3]. EMT marks the first step of the “metastasis 
cascade”, where epithelial cells of the primary tumor 
acquire mesenchymal-like traits. This way, epithelial 
cells lose their cell-cell adhesion and apical-basal polarity 
and change to a fibroblastic phenotype, modulate the 
organization of their cytoskeleton and gain the ability 
to migrate individually and invade basement membrane 
and blood vessels. Upon intravasation these cells stay 
in the bloodstream as circulating tumor cells, until they 
exit at some distant organs to initiate their colonization 
[3, 4]. Epithelial cells that undergo the EMT lose 
epithelial markers expression - such as E-Cadherin - 
while they acquire mesenchymal ones, like vimentin and 
N-Cadherin [5].
Different signaling pathways like TGF-β, EGF, 
HGF, Notch, FGF, Wnt, and IGFs [6], as well as 
mechanical factors such as extracellular matrix density 
[7], control EMT. These signals activate one of the EMT-
inducing transcription factors – TWIST1, SNAIL1, 
SNAIL2 (SLUG), ZEB1, ZEB2 (SIP1), Brachyury, 
Goosecoid, SIX1, and PRRX1 – that directly or indirectly 
repress the hallmark of epithelial phenotype, E-Cadherin 
expression. On the other hand, EMT can be inhibited 
by p53, mesenchymal-epithelial (MET)-inducing 
transcription factors such as GRHL2 and ELF5, and 
microRNA (miR) families like miR-200 and miR-34 [8].
Glypican-3 (GPC3) is a member of the heparan 
sulphate proteoglycan family that is attached to the cell 
surface by a glycosylphosphatidylinositol (GPI) anchor. 
Expression of GPC3 is substantial in trophoblasts and a 
number of embryonic tissues [9]. Modulation of its levels 
in a stage- and tissue specific manner has already been 
shown, suggesting an involvement in morphogenesis [10, 
11]. It was reported that in the adult, GPC3 is expressed 
only in a few tissues including mesothelium, and the 
ovarian and mammary epithelia [12, 13]. In spite of the 
fact that proteoglycans, which are strategically located 
on the surface of the extracellular matrix (ECM) cells 
and in the pericellular matrix, are a key component in 
stromal-epithelial interactions and signaling [14], only 
a few scientists have addressed their role under normal 
conditions in the healthy breast [15].
There are several studies which have linked GPC3 
with cancer [16]. In this regard, GPC3 overexpression 
has been shown in Wilms’ tumor [17], hepatocellular 
carcinoma (HCC) [18–20], yolk sac tumor and clear cell 
ovarian carcinoma [21]. In contrast, GPC3 expression is 
downregulated in lung adenocarcinoma [22], cell clear 
renal carcinoma [23], mesothelioma, ovarian [24, 25] 
and gastric cancer [26]. Regarding breast cancer, we have 
recently performed comparative studies of GPC3 expression, 
indicating lower GPC3 levels in tumors as compared to 
peritumor tissues [27]. In summary, depending on the 
tissue, GPC3 displays a very different pattern of expression 
during tumor progression. In tumors originated from 
tissues that only express GPC3 in the embryonic stage, the 
expression of this glypican tends to reappear upon malignant 
transformation. On the other hand, in cancers originated 
from tissues that are GPC3-positive in the adulthood, the 
expression of GPC3 is reduced during tumor progression. 
It is speculated that this tissue-specific differences are due to 
the fact that GPC3 is regulating different growth and survival 
factors in each tissue [16]. In this regard, we previously 
showed that the ectopic expression of GPC3 in the LM3 
murine mammary adenocarcinoma cell line was able to 
inhibit invasion and metastasis [28]. Although the GPC3 
signaling mechanism is not completely elucidated, we found 
that GPC3 re-expressing murine cells displayed an inhibition 
of the canonical Wnt signaling as well as an activation of the 
non-canonical Wnt/PCP pathway [29]. We also demonstrated 
that GPC3 re-expression inhibited the PI3K/AKT pathway 
and stimulated the p38 MAPK cascade [30].
In view of the clinical and translational usefulness of 
GPC3, in the current study we generated and characterized 
engineered human breast cancer cells to evaluate the 
role of GPC3 on human mammary tumor progression. 
We present in vitro and in vivo experimental evidence 
supporting the hypothesis that GPC3 has a protective role 
against human breast cancer progression. Furthermore, 
in this work we demonstrate that GPC3 induces MET. 
GPC3 expressing cells exhibit an epithelial phenotype, 
change their cytoskeleton organization, reduce their 
migration and clonogenic abilities, are more susceptible 
to cell death, exhibit higher homotypic adhesion, express 
epithelial markers while lose mesenchymal ones and are 
less invasive/metastatic. We showed that when human 
mammary tumor cells express GPC3, the canonical Wnt 
pathway is inhibited, the transcription factors ZEB1 is 
downregulated and the key marker of epithelial phenotype 
E-Cadherin is upregulated. So, cell-cell contacts are 
stabilized and cell detachment is diminished, thereby 
inhibiting the invasive and metastatic capacity of breast 
tumors.
RESULTS
Generation of engineered breast cancer cells
Analysis of GPC3 expression in breast cancer human 
cell lines
To study whether human breast cancer cell lines 
express GPC3, a qRT-PCR analysis was performed. Two 
groups of cell lines representing different stages of the 
disease were chosen (Table 1). Our results suggested 
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that the GPC3 mRNA expression level was opposite to 
the invasive and metastatic abilities of the studied human 
cell lines. The invasive and metastatic Hs578T and MDA-
MB231 cell lines expressed lower GPC3 mRNA levels 
than the poorly metastatic ZR-75-1 and MCF-7 cell lines 
(p<0.05 Hs578T vs. MCF-7 and MDA-MB231 vs. ZR-
75-1, p<0.01 MDA-MB231 vs. MCF-7, Figure 1A, left 
panel). In addition, 2.77 times higher levels of GPC3 
mRNA were found in MCF10A mammary normal-like 
cells than in MCF-7 cells (p<0.01, data not shown). We 
confirmed the GPC3 expression at protein level by WB 
in selected cell lines (MCF-7 and MDA-MB231) (Figure 
1A, right panel).
Silencing of GPC3 expression
Since MCF-7 was the cell line that expressed 
the highest levels of GPC3 (Figure 1A), we decided to 
inhibit GPC3 expression by means of shRNA technology. 
As was described in Materials and Methods, we used 
three shRNA sequences specific for GPC3 (designed as 
sh1, sh2 and sh3), as well as a shRNA scramble and a 
shRNA GAPDH sequences as controls (Table 2). After 
selection with G418, antibiotic-resistant colonies were 
screened for GPC3 expression by qRT-PCR (Figure 1B, 
left panel). Since the greatest silencing was obtained 
with the sh3 construction, we decided to clone this cell 
subline (called MCF-7-sh3). We selected one clone, 
named MCF-7-sh3 C2, with 95% of reduction in the 
GPC3 mRNA expression levels (p<0.001 MCF-7-sh3 
and MCF-7 sh3 C2 vs. MCF-7-sh scramble, Figure 1B, 
left panel). GPC3 depletion was also validated at protein 
level by WB (Figure 1B, right panel).
Overexpression of GPC3
Given that the MDA-MB231 malignant tumor cell 
line presented the lowest level of GPC3 (Figure 1A), we 
chose this cell line to overexpress GPC3. We performed 
one (MDA-MB231-GPC3x1) or two (MDA-MB231-
GPC3x2) rounds of infection with lentivirus containing 
the GPC3 cDNA or with the empty vector (MDA-
MB231-vector) as control. When we evaluated the 
expression of GPC3 using qRT-PCR, we detected a 
5 fold increase of the GPC3 mRNA levels in MDA-
MB231-GPC3x1 cells, whereas this increase was 10 
times higher in the MDA-MB231-GPC3x2 cells (p<0.01 
MDA-MB231-GPC3x1 vs. MDA-MB231-vector, 
p<0.001 MDA-MB231-GPC3x2 vs. MDA-MB231-
vector, Figure 1C, left panel). Overexpression of GPC3 
was also determined at the protein level (Figure 1C, 
right panel).
Characterization of the breast cancer cells with 
genetically modified GPC3 expression
In vitro cell behavior
Cell morphology
Although MCF-7-sh3 and control cells were 
morphologically similar and grew as monolayer 
of epithelial polyhedral cells, we found that GPC3 
overexpressing MDA-MB231 cells lost their fibroblast-
like appearance, acquiring an epithelial morphology 
(Figure 2A).
To analyze in detail the morphological change 
induced by GPC3, F-Actin organization was examined 
using phalloidin-FITC staining. We processed the confocal 
images and generated a graphic depiction where the x-axis 
represented the distance across the cell and the y-axis 
symbolized the level of fluorescence. It was determined 
that, although the actin of MCF-7 cells appeared mainly 
in the cortical position as was expected for epithelial cells, 
GPC3 silencing induced the assembly of few F-Actin 
stress fibers (Figure 2B). In addition, although control cells 
showed large actin stress fibers, GPC3 overexpression in 
MDA-MB231 cells induced the loss of these fibers and the 
re-localization of actin mainly in a cortical cell distribution 
(Figure 2B).
Table 1: Characteristics of the human breast cancer cell lines
Cell Line Histopathological 
Type









- - high moderate/high
HS578T Carcinosarcoma Primary Tumor - - high High




+ + moderate/low Null





+ + low Null
ER: estrogen receptor; PR: progesterone receptor; + Positive; - Negative
Table based on previously published data [41].
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Figure 1: GPC3 expression in breast cancer cell lines. A, B, C. Left panel: GPC3 mRNA expression levels were identified by 
qRT-PCR analysis of MDA-MB231, Hs578T, ZR-75-1 and MCF-7 (A), MCF-7-scramble, MCF-7-sh1, MCF-7-sh2, MCF-7-sh3 and MCF-
7-sh3 C2 (B), MDA-MB231-vector, MDA-MB231-GPC3x1 and MDA-MB231-GPC3x2 (C) cells. GAPDH was used as control. Values are 
expressed as mean ± SD. The data are representative of three independent experiments. (*p<0.05, **p<0.01, ***p<0.001 ANOVA, Tuckey 
test). Right panel: WB analysis was used to determine GPC3 protein expression in MDA-MB231 and MCF-7 (A), MCF-7-sh scramble, 
MCF-7-sh3 and MCF-7-sh3 C2 (B), MDA-MB231-vector, MDA-MB231-GPC3x1 and MDA-MB231-GPC3x2 (C) cells. β-Actin was used 
as an internal control. The arrow indicates the GPC3 protein core and the bracket indicates the glycanated fragments. Black lines highlight 
spliced lanes within a gel. Numbers on the right represent molecular mass (kDa).
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Cell growth properties
To investigate the ability of the engineered 
sublines to grow at low density, we performed 
clonogenic assays. The results showed that GPC3 knock 
down induced a significant increase in the clonogenicity 
of MCF-7 cells, while GPC3 overexpression suppressed 
MDA-MB231 clonogenic capacity (p<0.001 MCF-
7-sh3 and MCF-7-sh3 C2 vs. MCF-7-sh scramble; 
p<0.001 MDA-MB231-GPC3x1 and MDA-MB231-
GPC3x2 vs. MDA-MB231-vector, Figure 3A).
We also tested the anchorage-independent growth 
and checked that GPC3 silencing did not induce significant 
changes in the organization of MCF-7 spheroids 
(Figure 3B). Interestingly, although MDA-MB231 cells 
were unable to form spheroids, they acquired this ability 
when GPC3 was overexpressed (Figure 3B).
Overall, these data indicate that GPC3 suppressed 
low density growth as well as activated cell-cell adhesion 
and spheroids formation of the mammary cancer cells.
Susceptibility to cell death induction
To further investigate the functional role of GPC3 
in breast cancer, the sensitivity of the different sublines to 
nutrient depletion was tested.
After 72 h of starving we found, through Trypan 
Blue vital staining, that GPC3 silencing induced an 
increase in the MCF-7 cells viability (Figure 4A). Similar 
results were obtained by Propidium Iodide / Höechst 
staining (p<0.05 MCF-7-sh3 C2 vs. MCF-7-sh scramble, 
p<0.01 MCF-7-sh3 vs. MCF-7-sh scramble, Figure 4B). 
Although it was reported that MCF-7 cells have a lower 
probability to die through caspase-dependent apoptosis 
[31], we found that 10% of MCF-7-sh scramble cells 
showed apoptotic morphological characteristics when 
they were stained with Acridine Orange / Ethidium 
Bromide, but only about 5% of GPC3 silenced MCF-7 
cells exhibited these features (p<0.01 MCF-7-sh3 C2 vs. 
MCF-7-sh scramble, Figure 4C).
On the other hand, GPC3 overexpression induced 
a significant reduction in the number of MDA-MB231 
viable cells after starving (p<0.001 MDA-MB231-
GPC3x1 and MDA-MB231-GPC3x2 vs. MDA-MB231-
vector, Figure 4A). Propidium Iodide / Höechst staining 
revealed that MDA-MB231-GPC3 cells were more 
susceptible to death under stress conditions (p<0.01 
MDA-MB231-GPC3x1 and MDA-MB231-GPC3x2 vs. 
MDA-MB231-vector, Figure 4B). Although less than 
5% of control cells showed morphological evidence 
of apoptosis, the overexpression of GPC3 induced a 
high number of MDA-MB231 cells with nuclear and 
cytoplasmic apoptosis features (p<0.05 MDA-MB231-
GPC3x1 and MDA-MB231-GPC3x2 vs. MDA-MB231-
vector, Figure 4C).
Similar results were obtained when sublines were 
submitted to Doxorubicin treatment (data not shown).
Migration ability
In vitro wound assays were performed to analyze 
the migration of engineered cells. Compared to the 
control group, the silencing of GPC3 stimulated MCF-
7 cell migration (p<0.001 MCF-7-sh3 and MCF-7-sh3 
C2 vs. MCF-7-sh scramble). On the other hand, we 
also determined that MDA-MB231-GPC3 cells were 
significantly less mobile than controls (p<0.001 MDA-
MB231-GPC3x1 and MDA-MB231-GPC3x2 vs. MDA-
MB231-vector, Figure 5).
In vivo biological behavior
To confirm the functional role of GPC3 in breast 
cancer progression, MCF-7 and MDA-MB231 engineered 
cells were subcutaneously inoculated into nude mice.
We determined that 60% (3/5) of mice inoculated 
with MCF-7 control as well as MCF-7-sh3 C2 cells 
developed tumors. On the other hand, GPC3 overexpression 
significantly decreased MDA-MB231 tumor incidence. In 
fact, only 20% (2/10) of mice inoculated with MDA-MB231-
GPC3x2 cells developed tumors, as opposite to 63.6% (4/6) 
of mice with tumors in the control group (p< 0.05, Table 3).
All MCF-7 tumors grew at a similar rate. Although 
few animals inoculated with MDA-MB231-GPC3x2 
cells developed tumors, those were bigger than MDA-
MB231-vector tumors (p<0.001, Table 3 ). However, 
histopathology revealed that GPC3 overexpressing tumors 
Table 2: shRNA specific sequences used to silence GPC3 expression in MCF-7 cell line
Name Target sequence ΔG Hairpin 
(Kcal/mol)
Loop Tm (°C)
sh1 GGCTCTGAATCTTGGAATTGA -35.8 7 nt 114
sh2 GCCGAAGAAGGGAACTAATTC -38.0 7 nt 113
sh3 GGGACTGATGGTTAAACC -35.6 7 nt 114
sh scramble GTTCTCCGAACGTGTGTCACGT -31.8 9 nt 121
sh GAPDH GTATGACAACAGCCTCAAG -29.0 7 nt 111
sh1: shRNA GPC3 1; sh2: shRNA GPC3 2; sh3: shRNA GPC3 3; sh scramble: shRNA scramble; sh GAPDH: shRNA 
GAPDH; nt: nucleotide
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had a large necrotic core, inducing an overestimation of 
the final tumor volume (Figure 6A, inset).
Histopathological study of s.c. tumors showed 
differences in the invasiveness behavior. Although 33.33% 
(1/3) of GPC3 silenced MCF-7 tumors presented an 
invasion of the s.c. muscle and occasionally the dermis, 
MCF-7 tumors were unable to invade these tissues (p=0.06 
borderline significance, Table 3  and Figure 6A). In turn, 
GPC3 overexpression inhibited the invasive phenotype 
of MDA-MB231 cells. We have demonstrated that 75% 
(3/4) of control tumors invaded the s.c. muscle as well 
as the dermis, but no invasion was detected in GPC3 
overexpressing tumors (p<0.05, Table 3  and Figure 6A).
To evaluate the spontaneous metastatic capacity, 
lung nodules were studied under lens and by histological 
staining. All cell sublines only metastasized to lungs, 
being unable to colonize other organs. No spontaneous 
surface metastases were found. However, histopathology 
revealed the presence of parenchymatous nodes and 
micrometastatic/metastatic foci in the lungs of 60 % (3/5) 
of mice inoculated with GPC3 silenced MCF-7 cells. It 
is important to note that the lungs of 100% (5/5) of the 
animals inoculated with MCF-7-sh control cells were free 
of metastasis (p<0.05, Table 3  and Figure 6B). At the 
same time, although lung metastasis was found in 50% 
(3/6) of animals inoculated with MDA-MB231 control 
cells, there was no metastasis in lungs of mice injected 
with MDA-MB231-GPC3 cells (p<0.01, Table 3  and 
Figure 6B). These results indicate that GPC3 inhibits the 
metastatic ability of human breast cancer cells.
EMT markers
Since we found a severe morphological change 
in the GPC3 transduced MDA-MB231 cells - from 
fibroblast-like to squamous-epithelial cell shape - besides 
modulation on the actin cytoskeleton, growth, death, 
Figure 2: Effect of GPC3 on cell morphology and actin cytoskeleton organization. A. Morphological characteristics of 
MCF-7 and MDA-MB231 cell sublines. Representative Bright Field (BF) images are shown (Magnification x200, scale bars 40 μm). 
B. Fluorescence microscope analysis of actin cytoskeleton in MCF-7 and MDA-MB231 cell sublines after phalloidin-FITC staining. 
Nuclei were stained with DAPI. Representative images are shown (Magnification x600, scale bars 10 μm). The scatter plots represent the 
quantification of fluorescence intensity across the lines of 12 cells of each group using ImageJ software.
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migration, and in vivo behavior, in MCF-7-sh GPC3 
and MDA-MB231-GPC3 cells, we decided to study the 
potential role of GPC3 in the EMT of breast cancer cells. 
We further examined the expression of the epithelial 
marker E-Cadherin.
Confocal laser scanning microscopy images of 
GPC3 silenced MCF-7 cells showed a decrease in the 
E-Cadherin expression (Figure 7A, upper panel). This 
was also demonstrated by WB and qRT-PCR (p<0.01 
MCF-7-sh3 and MCF-7-sh3 C2 vs. MCF-7-sh scramble, 
Figure 7A, middle and lower panel). Moreover, although 
MDA-MB231 cells did not express E-Cadherin, we 
demonstrated by IF, WB and qRT-PCR that GPC3 
induced the re-expression of this epithelial marker 
(p<0.01 MDA-MB231-GPC3x2 vs. MDA-MB231-
vector, Figure 7A). Images of the MDA-MB231-GPC3 
cells revealed strong E-Cadherin staining in cell-cell 
junctions. To confirm the functionality of E-Cadherin, we 
conducted a homotypic adhesion assay in the presence 
of anti E-Cadherin neutralizing antibody. As expected, 
MCF-7 cells failed to form spheroids when E-Cadherin 
was blocked (Figure 7B). Interestingly, we did not obtain 
spheroids when MDA-MB231-GPC3 cells were pre-
incubated with the E-Cadherin neutralizing antibody 
(Figure 7B). Assays with an isotype control corroborated 
the antibody specificity (Figure 7B, third photo of each 
panel).
Given the radical modulation of the epithelial 
marker E-Cadherin found in the MDA-MB231 breast 
cancer sublines, we decided to analyze the expression 
of the mesenchymal markers N-Cadherin and vimentin. 
By means of WB, we established that MCF-7 cells were 
unable to express these EMT-related markers at protein 
level. However, using qRT-PCR, a significant upregulation 
of N-Cadherin mRNA levels could be observed when 
GPC3 was silenced (p<0.01 MCF-7-sh3 and MCF-7-sh3 
C2 vs. MCF-7-sh scramble, Figure 8A). Meanwhile, the 
high expression levels of these mesenchymal markers 
detected in MDA-MB231 cells were reduced when GPC3 
was overexpressed (Figure 8B).
These data demonstrate that GPC3 induced MET in 
breast cancer cells.
Figure 3: Effect of GPC3 on cell growth properties. A. Clonogenic assays were employed to test the ability to grow at low density 
of MCF-7-sh scramble, MCF-7-sh3 and MCF-7-sh3 C2, as well as MDA-MB231-vector, MDA-MB231-GPC3x1 and MDA-MB231-
GPC3x2 cells. Values are expressed as mean ± SD. The figure shows the results of one of three independent experiments. (***p<0.001 
ANOVA, Tuckey test). B. The anchorage-independent 3D growth potential of MCF-7 and MDA-MB231 cell sublines was examined by the 
spheroids formation. Images were taken under inverted phase contrast microscope and are representative of two independent experiments 
(Magnification x40, scale bars 200 μm).
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Figure 4: Effect of GPC3 on susceptibility to cell death. A. After 72 h starving, the number of MCF-7-sh scramble, MCF-7-sh3 
and MCF-7-sh3 C2, as well as of MDA-MB231-vector, MDA-MB231-GPC3x1 and MDA-MB231-GPC3x2 viable cells was evaluated by 
Trypan blue staining (*** p<0.001 ANOVA, Tuckey test). B. Starved MCF-7 and MDA-MB231 cell sublines were stained with propidium 
iodide / Höescht and the cell death rate was calculated (*p<0.05, **p<0.01 ANOVA, Dunnett test). C. Acridine orange / ethidium bromide 
staining was employed to evaluate apoptotic cell death. The number of apoptotic cells was recorded and plotted (*p<0.05, **p<0.01 
ANOVA, Dunnett test). Characteristic images are showed (Magnification x400, scale bars 20 μm). A, B and C values are expressed as mean 
± SD and data are representative of three independent experiments.
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Regulatory mechanism of E-Cadherin 
expression: Wnt/β-Catenin signaling pathway 
and EMT-transcription factors
It was reported that the canonical Wnt/β-Catenin 
pathway could participate in the EMT process of breast 
cancer cells [32]. To reveal the potential mechanism 
of MET induction by GPC3, we studied the canonical 
Wnt signaling activation. We analyzed cytoplasmic 
β-Catenin levels, since it was demonstrated that they are 
representative of the pathway activity [33]. We used the 
nuclear marker H3 as a cytoplasmic fraction purity control. 
WB results showed that cytoplasmic/total β-Catenin ratio 
increased in GPC3 silenced MCF-7 cells compared to 
control cells (Figure 9A, upper panel). In addition, MDA-
MB231-GPC3 cells displayed lower cytoplasmic/total 
β-Catenin ratio compared to control cells (Figure 9A, 
upper panel). To corroborate these results, we decided 
to analyze nuclear β-Catenin levels as a most direct way 
to assess canonical Wnt transcriptional activity. Through 
confocal immunofluorescence we established that the 
nuclei of GPC3 silenced MCF-7 cells presented about 
60% more β-Catenin fluorescence intensity than the nuclei 
of MCF-7-sh scramble cells (p<0.05 MCF-7-sh3 and 
MCF-7-sh3 C2 vs. MCF-7-sh scramble). Meanwhile, the 
nuclear β-Catenin fluorescence level was reduced about 
25% in GPC3 overexpressing MDA-MB231 cells (Figure 
9A, lower panel). Taken together, both assays indicate that 
GPC3 is inhibiting canonical Wnt signaling.
Next, we decided to prove whether GPC3 induces 
MET through the inhibition of Wnt/β-Catenin signaling. 
To do this, we reversed the inhibitory effect of GPC3 on 
the canonical pathway in MDA-MB231 cells using the 
activator LiCl as was described [34]. Lithium acts through 
inhibition of glycogen synthase kinase-3 beta (GSK-
3β), preventing the constitutive proteasome-mediated 
degradation of cytoplasmic β-Catenin. This results in 
the accumulation and nuclear translocation of β-Catenin, 
where it induces β-Catenin/TCF-mediated transcriptional 
activity [35].
First, we corroborated that LiCl activates the 
canonical Wnt pathway in our cells. MDA-MB231-vector 
and MDA-MB231-GPC3 cells were treated with LiCl (or 
NaCl as control) and analyzed by WB and IF. As seen in 
Figure 9B, left panel, the treatment with LiCl induced an 
increase in the cytoplasmic β-Catenin levels, suggesting 
the activation of canonical Wnt signaling. This was 
confirmed by IF. Nuclear β-Catenin fluorescence intensity 
increased 30% in the MDA-MB231-GPC3x1 cells treated 
with LiCl (p<0.05), whereas this increment was about 
Figure 5: Effect of GPC3 on cell migration. Wound healing assays were employed to test the migratory capacity of MCF-7 and 
MDA-MB231 cell sublines. Migration is expressed as the percentage of wound coverage area (mean ± SD). Representative images are 
shown (Magnification, x200. Scale bars, 40 μm), where red line indicates the migration front. Data are representative of three independent 
experiments (***p<0.001 ANOVA, Tuckey test).
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Figure 6: Effect of GPC3 on the in vivo cell behavior. A. Eight-to-ten week old females nude mice (n = 5 to 10 mice/group) were 
inoculated with MCF-7 (-sh scramble and -sh3 C2) and MDA-MB231 (-vector and -GPC3x2) cells. MCF-7 cells-bearing mice received 
pellets of 0.5 mg 17-β-estradiol. Representative photographs of tumors are shown (Magnification x40, Scale bar 200 μm). Arrows indicate 
the tumor. Inset shows MDA-MB231-GPC3x2 tumor core (Magnification x100). B. The lungs of tumor-bearing mice were removed and 
examined for metastases under a dissecting microscope and by histological staining. Representative images are shown (Magnification x40, 
Scale bar 200 μm). Arrows indicate micrometastatic/metastatic foci. Data are representative of three independent experiments.
Table 3: Effect of GPC3 on the in vivo cell behavior
MCF-7-shscramble MCF-7-sh3C2 MDA-MB231-vector MDA-MB231-
GPC3x2
Tumorigenicity (%, n/n) 60 (3/5) 60 (3/5) 63.63 (4/6) 20 (2/10) *
Tumor Growth Rate  
(mm3/day) 120 ± 10 130 ± 20 120 ± 30 500 ± 140 
+++
Histological Invasion (%, n/n) 0 (0/3) 33.33 (1/3) 75 (3/4) 0 (0/2) #
Spontaneous  
Metastasis Incidence (%) 0 (5/5) 60 (3/5) 
& 50 (3/6) 0 (0/10) ♠♠
Tumorigenicity: n of animals that developed tumors/ n of injected animals. Histological invasion: n of animals with tumors 
presenting local invasion / n of animals with tumors. Spontaneous metastasis incidence: n of animals presenting distant 
metastasis / n of animals. +++ p<0.0001 MDA-MB231-GPC3x2 vs. MDA-MB231-vector, Comparing slopes test; * p<0.05 
MDA-MB231-GPC3x2 vs. MDA-MB231-vector, # p<0.05 MDA-MB231-GPC3x2 vs. MDA-MB231-vector, & p<0.05 
MCF-7-sh3 C2 vs.MCF-7-sh scramble,♠♠ p<0.01 MDA-MB231-GPC3x2 vs. MDA-MB231-vector, Chi-square test.
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Figure 7: Effect of GPC3 on the expression of the epithelial marker E-Cadherin. A. E-Cadherin expression was evaluated in 
MCF-7-sh scramble, MCF-7-sh3 and MCF-7-sh3 C2 as well as MDA-MB231-vector, MDA-MB231-GPC3x1 and MDA-MB231-GPC3x2 
by IF (Magnification x1000. Scale bars 8 μm), WB and qRT-PCR. β-Actin was used as a WB internal control, while GAPDH was employed 
as a qRT-PCR control (**p<0.01 ANOVA, Dunnett test). B. The anchorage-independent 3D growth ability of cell sublines, growing in 
the presence of anti E-Cadherin neutralizing antibody, was examined after 48 h culture. Representative images were taken under inverted 
phase contrast microscope (Magnification x40. Scale bars 200 μm). Data on the isotype control are shown in the third photo of each panel.
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200% in MDA-MB231-GPC3x2 lithium treated cells 
(p<0.05, Figure 9B, right panel).
Later on, we evaluated the expression of E-Cadherin 
(target downregulated by Wnt pathway). However, no 
changes were found in E-Cadherin expression when 
MDA-MB231-GPC3 cells were treated with LiCl 
(Figure 9C). In other words, GPC3 was able to stimulate 
the E-Cadherin re-expression in MDA-MB231 cells even 
when the canonical Wnt signaling is activated. These 
results indicate that GPC3 induced MET independently of 
canonical Wnt/β-Catenin signaling.
It has been reported that EMT-transcription factors 
can regulate E-Cadherin expression in specific cellular 
contexts and control the EMT program [5]. Therefore, the 
mRNA levels of SNAIL1, SNAIL2 (SLUG), and ZEB1 
were determined by qRT-PCR. The results showed that 
ZEB1 expression was significantly increased in GPC3 
silenced MCF-7 cells (p<0.05 MCF-7-sh3 and MCF-7-
sh3 C2 vs. MCF-7-sh scramble, Figure 10A, upper panel). 
Conversely, MDA-MB231 cells significantly decreased 
the ZEB1 mRNA levels when GPC3 was overexpressed 
(p<0.01 MDA-MB231-GPC3x1 and MDA-MB231-
GPC3x2 vs. MDA-MB231-vector, Figure 10A, upper 
panel). This modulation was confirmed at protein level 
by WB (Figure 10A, lower panel). The other transcription 
repressors did not present relevant changes (data not 
shown).
In order to corroborate whether GPC3 induced 
the re-expression of E-Cadherin in MDA-MB231 cells 
through the downregulation of the transcriptional repressor 
ZEB1, we transfected MDA-MB231-GPC3 cells with a 
vector encoding ZEB1 (empty vector was used as control). 
As seen in Figure 10B, the expression of E-Cadherin was 
inhibited when MDA-MB231-GPC3 cells overexpressed 
ZEB1. In other words, GPC3 induces the E-Cadherin 
upregulation by inhibiting ZEB1 expression.
Next, we examined whether the in vitro GPC3 effect 
on the expression of ZEB1 and E-Cadherin was maintained 
in vivo. With this aim, MCF-7-sh scramble, MCF-7-sh3 
C2, MDA-MB231-vector and MDA-MB231-GPC3x2 
tumors were analyzed by IHC. The assays revealed ZEB1 
expression in nuclei, cytoplasm and atypically in the 
stroma of different tumors (Figure 10C). For analysis, 
only unequivocal nuclear staining was accepted as positive 
[36, 37]. Nuclear ZEB1 was detected in 61.5 ± 13.8% of 
cells from MCF-7-sh scramble tumors, compared to 97.2 
± 8.0% of positive cells found in MCF-7-sh3 C2 tumors 
(p<0.001). Moreover, 73.0 ± 15.1% of cells from MDA-
MB231-vector tumors showed positive staining for ZEB1, 
while 33.2 ± 3.2% of cells of GPC3 overexpressing tumors 
did it (p<0.01). On the other hand, IHC revealed positive 
E-Cadherin staining mainly at the plasma membrane of 
the tumor cells, as expected. As shown in Figure 10C, all 
cells from MCF-7-sh scramble tumors were positive for 
this epithelial marker. Although the most of the cells of the 
MCF-7-sh3 C2 tumors remained positive for E-Cadherin, 
we observed a decrease in the intensity of staining. 
Contrarily, most of MDA-MB231-vector tumor cells were 
negative for E-Cadherin, while 95.0 ± 5.2% of MDA-
MB231-GPC3 tumor cells expressed this protein (p<0.001).
Figure 8: Effect of GPC3 on the expression of the mesenchymal markers N-Cadherin and vimentin. A, B. WB and qRT-
PCR techniques were used to analyze N-Cadherin (A) and vimentin (B) expression. For WB, β-Actin was used as an internal control and 
numbers on the left indicate molecular mass (kDa). For qRT-PCR, GAPDH was employed as control, and values are expressed as mean ± 
SD. The data are representative of three independent experiments (**p<0.01 ANOVA, Dunnett test).
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Figure 9: Effect of GPC3 on the canonical Wnt/β-Catenin signaling pathway activity. A. Upper panel: Cytoplasmic and 
total protein extracts from MCF-7 and MDA-MB231 cell sublines were analyzed by WB using an anti β-Catenin antibody. Loading was 
standardized by β-Actin levels for each fraction, and the cytoplasmic/total β-Catenin ratio was calculated and presented in the histogram. 
H3 antibody was employed as nuclear marker. Numbers on the left represent molecular mass (kDa). Lower panel: Confocal IF was 
performed to quantify nuclear β-Catenin intensity, where DAPI was used to define the nucleus. Quantitative microscopy measurements 
were performed in individual cells (13-76 cells for each subline) and they are indicated below the microphotographies. Representative 
images are shown (Magnification x600, Scale Bar 10 μm) (*p<0.05 ANOVA, Tuckey test). B. MDA-MB231-GPC3 sublines were treated 
with LiCl (20 mM) or NaCl (20 mM) as control. Left panel: The activation of canonical Wnt pathway induced by lithium was tested 
by cytoplasmic β-Catenin accumulation through WB. Right panel: Confocal IF was performed to quantify nuclear β-Catenin intensity 
(*p<0.05 ANOVA, Tuckey test). C. WB was used to analyze E-Cadherin expression in MDA-MB231-vector, MDA-MB231-GPC3x1 
and MDA-MB231-GPC3x2 cells treated with LiCl (20 mM) or NaCl (20 mM) as control. α-Tubulin was used as an internal control and 
numbers on the left indicate molecular mass (kDa).
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Figure 10: Effect of GPC3 on the expression of the transcriptional repressor ZEB1. A. ZEB1 mRNA levels were analyzed 
by qRT-PCR (upper panel) and ZEB1 protein expression was determined by WB (lower panel), in MCF-7 and MDA-MB231cell sublines. 
In qRT-PCR reactions, GAPDH was used as an internal control. Values are expressed as mean ± SD (*p<0.05, **p<0.01 ANOVA, Dunnett 
test). In WB, loading was standardized by β-Actin levels. Numbers on the right represent molecular mass (kDa). The data are representative 
of two independent experiments. B. Protein extracts from MDA-MB231-GPC3 cells transfected with a plasmid encoding ZEB1 (or with 
the empty vector as control) were analyzed by WB. The expression levels of ZEB1 and E-Cadherin were determined. β-Actin was used 
as an internal control. Numbers on the right indicate molecular mass (kDa). The data are representative of three independent experiments. 
C. ZEB1 and E-Cadherin expression was evaluated at protein level by IHC, in MCF-7-sh scramble, MCF-7-sh3 C2, MDA-MB231-vector 
and MDA-MB231-GPC3x2 tumors. Representative images are shown. Original magnification x400, scale bar 20 μm.
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DISCUSSION
The plasticity that cells show during the EMT 
process is crucial to tumor metastasis development [3]. 
Cancer cells undergoing EMT can acquire invasion 
capability and enter surrounding tissues, a critical 
step of the metastatic cascade. Moreover, the effect of 
EMT not only includes increasing migration, invasion 
and metastatic potential, but also the acquisition of 
chemoresistance [3]. So, we consider that discovering 
molecules able to revert EMT (or to promote MET) is key 
for the development of effective anticancer therapeutics.
Although historically only mechanical and structural 
functions were attributed to proteoglycans, more recent 
studies have highlighted their contribution in cell behavior 
control. In this study, we emphasize the inhibitory role 
of GPC3 on breast cancer progression. In addition, our 
findings underline the intimate connections between GPC3 
and the EMT program operating in tumorigenesis.
Here we study the role of GPC3 in breast cancer 
biology. GPC3 silencing induced the reorganization of the 
actin cytoskeleton, with the acquisition of few stress fibers 
by MCF-7 cells. Most notably, GPC3 overexpression in 
MDA-MB231 cells stimulated a dramatic morphological 
change, from a mesenchymal to an epithelial phenotype. 
Even more, the loss of stress fibers supports the idea that 
GPC3 induces a transition to an epithelial phenotype.
We also showed that GPC3 expression decreased the 
clonogenic efficiency of breast cancer cells, since GPC3 
silenced MCF-7 cells showed higher aptitude to grow at 
low density while GPC3 overexpressing MDA-MB231 
cells were less clonogenic than their controls. Supporting 
these results, it was reported that overexpression of GPC3 
in renal carcinoma [23] and in ovarian cancer [24, 25] cell 
lines, reduced their clonogenic efficiency. Our results also 
indicated that silencing GPC3 did not induce significant 
changes in the ability of MCF-7 cells to grow in 3D 
spatial organization, but its overexpression stimulated the 
formation of large MDA-MB231 spheroids. This is, to our 
knowledge, the first report indicating that GPC3 is able 
to modulate anchorage-independent 3D growth in breast 
cancer cells. Simultaneously with our work, Gao et. al. 
have reported that blocking the GPC3 heparan sulphate 
chains inhibited in vitro hepatocarcinoma spheroid 
formation [38]. All together, our results suggest that GPC3 
is able to modulate different growth properties of breast 
cancer cells.
On the other hand, we determined that GPC3 
expression increased the susceptibility to death. Although 
it was informed that the overexpression of GPC3 did 
not affect the apoptosis of renal carcinoma cells [23], 
our studies showed that MCF-7-sh GPC3 cells were less 
susceptible to death, while MDA-MB231-GPC3 died 
more after starvation. This behavior was also observed 
when cells were treated with Doxorubicin. In association, 
we have previously demonstrated that the re-expression 
of GPC3 induced a decrease in the apoptosis resistance 
acquired by the LM3 murine mammary adenocarcinoma 
cells [28, 30]. This pro-apoptotic role is supported by a 
previous report revealing that MCF-7 cells transfected 
with GPC3 gene generated fewer clones that those cells 
transfected with an inactive mutant of GPC3 [39]. On the 
contrary, it was shown that the GPC3 silencing leads to 
an increase in apoptosis of hepatocarcinoma cells [40]. 
In summary, our results show that GPC3 would act as 
an inductor of cell death in stressed breast cancer cells. 
The reported discrepancies reinforce the idea of the GPC3 
tissue specific role, highlighting once more the importance 
of tumor microenvironment.
Our wound healing assays indicated that silencing 
GPC3 stimulated motility of MCF-7 cells, while GPC3 
overexpression blocked MDA-MB231 cell migration. 
These results suggest that GPC3 inhibits the migratory 
ability of breast cancer cells. The same inhibitory effect 
has been reported for murine mammary tumor cells as 
well as for human ovarian cancer cell lines [28, 29, 41]. 
In contrast, GPC3 silencing leads to a decrease in the 
migratory capacity of hepatocellular carcinoma cell lines 
[42, 43].
To analyze whether GPC3 is able to modulate the 
invasive and metastatic behavior of the human breast 
cancer cell lines, we performed in vivo assays. We showed 
that GPC3 expressing s.c. tumors are less invasive and 
metastatic. Although MCF-7 control tumors grew in situ, 
GPC3 silencing stimulated these tumors to invade adjacent 
tissues and to metastasize. MDA-MB231 control tumors 
invaded the muscle and dermis as well as developed 
metastasis, but GPC3 overexpression inhibited these 
capabilities. In the same way, we have previously reported 
that GPC3 re-expression reduced the ability of the LM3 
murine mammary adenocarcinoma cells to invade the 
dermis and to form lung metastasis [28]. Therefore, we 
have suggested that GPC3 acts as a metastasis suppressor 
in breast cancer [3, 28]. In association, a paper recently 
published identifies GPC3 as a potential metastasis 
suppressor in gastric cancer [26].
All together, our in vitro and in vivo results show 
that GPC3 is able to promote MET in mammary tumor 
cells, inducing phenotypic changes and regulating 
growth, death, migration and invasive/metastatic ability. 
To confirm this hypothesis, we evaluated the expression 
of mesenchymal and epithelial markers. We found that 
the downregulation of GPC3 in MCF-7 cells inhibited 
E-Cadherin expression and increased N-Cadherin mRNA 
levels. Most notable was the difference found in the MDA-
MB231 cells, since GPC3 forced the re-expression of the 
epithelial marker E-Cadherin, while the mesenchymal 
markers N-Cadherin and vimentin were downregulated. 
Interestingly, we demonstrated that the E-Cadherin re-
expressed by MDA-MB231-GPC3 cells was functional, 
since these cells acquired the ability to form E-Cadherin-
dependent spheroids. Since E-Cadherin suppression in 
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cancer cells enhances the development of migratory and 
invasive phenotype and facilitates dissociation from the 
surrounding extracellular matrix of the primary tumor 
site [5], we suggest that GPC3 would induce MET by 
regulating E-Cadherin expression.
There are a number of signaling pathways involved 
in the EMT process. Among them, the classical Wnt/β-
Catenin pathway could participate in the EMT progression 
of cancer cells [29, 44, 45]. We demonstrated that 
cytoplasmic/total β-Catenin ratio increased in GPC3 
silenced MCF-7 cells, while this ratio decreased in 
GPC3 overexpressing MDA-MB231 sublines. This was 
also demonstrated by IF, where the levels of nuclear 
β-Catenin were analyzed. The experiments performed 
during our study confirm that the activity of the classical 
Wnt/β-Catenin pathway is inhibited by GPC3. This 
result is in accordance with our previous work, where 
we demonstrated that GPC3 is a modulator of Wnt 
signaling in murine mammary cancer cells, by inhibiting 
the canonical pathway and activating the non-canonical 
one [29]. Once again, highlighting the opposite role of 
GPC3 in hepatocarcinoma cells, it was informed that 
this glypican is able to activate Wnt/β-Catenin signaling 
pathway in this pathology [40].
Here we showed that the role of GPC3 in the EMT 
process is not related to the canonical Wnt signaling. We 
evaluated the E-Cadherin expression levels when the 
Wnt/β-Catenin pathway inhibition induced by GPC3 was 
reverted employing the activator LiCl. We determined 
that when MDA-MB231-GPC3 cells were incubated with 
LiCl, the expression levels of E-Cadherin did not change. 
Therefore, these results show that GPC3 is capable to 
induce MET independently of the canonical Wnt signaling 
pathway.
Although Wnt signaling is important for the 
regulation of the EMT program in diverse tumor cells, 
the above results are not unexpected. When canonical 
Wnt pathway is activated, β-Catenin translocates to the 
nucleus and forms a complex with T-cell factor/lymphoid 
enhancer factor (TCF/LEF) initiating the transcription 
of Wnt target genes, including SNAIL1 [46]. SNAIL1 
is one of the EMT-inducing transcription factors able to 
repress E-Cadherin. However, SNAIL1 expression was 
not modulated in our cells. There are others transcription 
factors, such as SNAIL2 (SLUG), ZEB1 and ZEB2, that 
directly or indirectly repress the hallmark of epithelial 
phenotype, the E-Cadherin expression [8]. Our results 
showed that GPC3 silencing induced the upregulation 
of ZEB1 in MCF-7 cells, while MDA-MB231-GPC3 
cells presented lower levels of ZEB1 as compared to 
controls. To confirm that GPC3 modulates the E-Cadherin 
expression downregulating ZEB1, MDA-MB231-
GPC3 cells were transfected with a vector encoding 
ZEB1. We determined that GPC3 is unable to induce 
the E-Cadherin re-expression in MDA-MB231 cells 
if ZEB1 is overexpressed. We also confirmed by IHC, 
that the modulation of ZEB1/E-Cadherin induced by 
GPC3 is maintained in in vivo tumors. All together, our 
results demonstrate that GPC3 induces the E-Cadherin 
upregulation through ZEB1 modulation. In association, 
Qin and collaborators have recently reported that hTERT 
promotes the colorectal cancer cells EMT independent of 
Wnt, through the ZEB1 pathway [47]. It has been reported 
that TGF-β, a major inducer of EMT [48], regulates the 
expression of target genes like ZEB [49]. Therefore, 
TGF-β pathway would be an alternative mechanism 
to mediate the ZEB1 modulation induced by GPC3. 
However, details of this EMT regulatory network remain 
unclear. Future mechanistic studies are needed to test this 
hypothesis.
In summary, our results indicate that GPC3 can 
modulate several mechanisms involved in mammary 
tumorigenesis and malignant progression. GPC3 induces 
MET through ZEB1 pathway, and controls growth, death, 
migration and metastatic spread of breast cancer cells. 
GPC3 might be a new therapeutic target for preventing 
breast cancer cell metastasis.
MATERIALS AND METHODS
Tumor cell lines
The human breast cancer cell lines MDA-MB231, 
Hs578T, ZR-75-1 and MCF-7 (Table 1) were obtained 
from the ATCC in 2008 (Manassas, VA, USA). The 
authentication of the cell lines used in this work were 
performed by examining up to 22 polymorphic loci 
for human and cell line STR profiling in accordance 
with the standard ASN-0002-2011 (DDC Medical, 
Fairfield, OH, USA. Validation date: July 16th 2015). An 
electropherogram provided the data generated by the STR 
DNA analysis.
All cell lines were grown in RPMI 1640 medium 
(Gibco Life Technologies, Carlsbad, CA, USA) with 
non-essential aminoacids and 2 mM L-glutamine, 
supplemented with 10% fetal calf serum (FCS) 
(Internegocios, BA, Argentina) and 80 mg/ml gentamicin, 
at 37°C in a humidified 5% CO2 - air atmosphere.
Quantitative Real-Time PCR (qRT-PCR)
Total RNA was extracted using TRIZOL 
reagent (Invitrogen Life Technologies, Carlsbad, CA, 
USA) according to the manufacturer’s instructions. 
RNA was quantified in a Nanodrop (Thermo 2000 
spectrophotometer) and cDNA was synthesized from 1 
μg of RNA previously treated with 10 Units of DNAsa 
I (Invitrogen Life Technologies, Carlsbad, CA, USA), 
using iScript cDNA synthesis kit (Bio-Rad Life Science, 
Hercules, CA, USA). The reaction conditions were as 
follows: a period of 5 min at 25°C, 30 min at 55°C and 
5 min at 95°C. The resulting cDNA was subsequently 
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treated with 1 Unit of RNase H (GE Healthcare, Little 
Chalfont, Buckinghamshire, UK).
qRT-PCR reactions contained: 3 μl cDNA (1:10), 
6 μl 2X SYBR Green Master Mix (Applied Biosystems 
Life Technologies, Carlsbad, CA, USA), and forward 
and reverse primers for GPC3, E-Cadherin, N-Cadherin, 
vimentin, SNAIL1, SNAIL2 (SLUG), ZEB1 and GAPDH 
(Table 2). Reactions were completed in a termocyler/
detector REAL TIME C1000 CFX96 (Biorad, Hercules, 
CA, USA). Cycle conditions were: 50°C 2 min, 95°C 10 
min and 40 cycles at 95°C for 15 sec and 60°C during 1 
min. 2−ΔΔCt was used to calculate relative gene/GAPDH 
expression. All samples were run in triplicate.
Western blot (WB)
Confluent monolayers were washed three times 
with ice cold PBS and then lysed with Lysis Buffer 
(PBS-1% Triton X-100) containing protease-inhibitors 
(Sigma-Aldrich, Saint Luis, MO, USA). In order to 
analyze whether canonical Wnt signaling is involved in 
E-Cadherin regulation, cells were treated 2 h with 20 mM 
LiCl (activator of canonical pathway) or with 20 mM 
NaCl as control. For analysis of cytoplasmic β-Catenin 
levels, cytoplasmic extracts were obtained using a saponin 
buffer, as previously described [29]. Briefly, cells were 
lysed with 250 ml of saponin lysis buffer (25 mM Hepes, 
75 mM potassium acetate, 0.1% saponin, phosphatase 
inhibitor cocktail and protease inhibitors). The extraction 
procedure was carried out twice; the extracts were pooled 
and then centrifuged.
Protein content of cell samples was determined 
by Bradford method. The samples were boiled in 
Laemmli sample buffer with 5% β-mercaptoethanol. 
WB analyses were carried out using a sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Electrophoresis gels were transferred to PVDF membranes 
using “Mini Trans-Blot module” (BioRad, Hercules, CA, 
USA). Non-specific binding was blocked by incubation of 
the membrane with TBS 5% skim milk for an hour. Then, 
membranes were incubated with the specific antibodies 
overnight at 4°C (1:1500 for hGPC3 mouse monoclonal 
antibody 1G12, kindly provided by Dr. Filmus; 1:1000 
for E-Cadherin mouse monoclonal antibody, BD 
Bioscience, San Jose, CA, USA; 1:1000 for β-Catenin 
mouse monoclonal antibody, BD Bioscience, San Jose, 
CA, USA; 1:1000 for vimentin rabbit monoclonal Abcam, 
Cambridge, MA , USA; 1:1000 for N-Cadherin rabbit 
polyclonal antibody, Abcam, Cambridge, MA , USA; 
1:500 for ZEB1 H102 rabbit polyclonal antibody, Santa 
Cruz Biotechnology, Dallas, TX, USA; 1:15000 for H3 
rabbit polyclonal antibody, EMD Millipore, Billerica, MA, 
USA; 1:5000 for β-Actin mouse monoclonal antibody 
Santa Cruz Biotechnology, Dallas, TX, USA; 1:1000 for 
α-Tubulin rabbit monoclonal antibody, Cell Signaling, 
Danvers, MA, USA). Membranes were subsequently 
blotted with peroxidase-conjugated goat anti-mouse 
(1:5000, Santa Cruz Biotechnology, Dallas TX, USA) or 
goat anti-rabbit (1:5000, Sigma-Aldrich St. Louis, MO, 
USA) secondary antibodies, for 1 h at room temperature. 
After that, detections were performed using ECL western 
blot reagents (Amersham-GE Healthcare, Little Chalfont, 
Buckinghamshire, UK). Electrophoretic band images were 
obtained and analyzed by densitometry (Optical Density, 
OD) by ImageJ1.49m program. In all WB, OD of each 
protein was standardized to the corresponding loading 
control OD (β-Actin or α-Tubulin as corresponded). 
To analyze cytoplasmic/total β-Catenin ratio, total and 
cytoplasmic extracts were resolved into the same gel. 
The cytoplasmic β-Catenin/β-Actin and total β-Catenin/
β-Actin relation values were calculated, and the ratio 
between these values (cytoplasmic/total) represented 
cytoplasmic β-Catenin accumulation.
Immunofluorescence (IF)
Cells were grown on glass coverslips, washed 
twice with PBS, fixed in 4% formaldehyde/PBS at RT 
for 15 min, permeabilized with PBS-0.1% Triton X-100 
for 10 min at 37°C and then blocked with PBS 5% BSA 
(ChemCruz, Dallas, TX, USA) for 1 h. E-Cadherin 
was detected by incubation with a primary monoclonal 
antibody (BD Bioscience, San Jose, CA, USA) diluted in 
PBS+5% BSA (1:100), followed by incubation with an 
anti-mouse IgG-Alexa 546 secondary antibody (1:500) 
for 1 h (Invitrogen-Thermo Fisher Scientific, Waltham, 
MA, USA). Nuclei were stained with DAPI. Images were 
obtained in an Olympus Fluo view FV 1000 microscope.
For F-Actin staining, coverslips were incubated for 
45 min at RT with phalloidin-FITC (Sigma-Aldrich, Saint 
Luis, MO, USA) (1:400) and cell nuclei were counter-
stained with DAPI. The coverslips were mounted with 
Mowiol 4-88 (Calbiochem, Darmstadt, Germany). Cells 
were imaged by confocal laser scanning microscopy, 
which was performed with an Olympus Fluo view FV 
1000 microscope, using an Olympus 60×/1.20 NA 
UPLAN APO water immersion objective and a 3x digital 
zoom. Excitation and emission filters were given as 
follows: DAPI: excitation, 405 nm; emission, band pass: 
430 to 470 nm. FITC: excitation, 488 nm; emission, band 
pass 505 to 525 nm. Confocal images were processed 
for presentation with FIJI (https://fiji.sc). Background of 
each channel was subtracted. Briefly, FIJI software was 
used to generate line profiles (13 μm length for MCF-7 
cells, 20 μm length for MDA-MB231 control cells and 
10 μm length for MDA-MB231-GPC3x1 and -GPC3x2 
cells). A graphic depiction was then generated where the 
x-axis represented the distance across the cell and the 
y-axis represented the level of fluorescence. We randomly 
selected 12 cells of each group for graphic depicting.
For nuclear β-Catenin analysis, monolayers were 
treated, as appropriate, with 20 mM LiCl or 20 mM NaCl 
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as control for 2 h. Coverslips were fixed in 70% ethanol 
at -20°C for 10 min, permeabilized with PBS-0.1% Triton 
X-100 for 10 min at 37°C and blocked with PBS 3% 
BSA (ChemCruz, Dallas, TX, USA) for 1 h. β-Catenin 
antibody (BD Bioscience, San Jose, CA, USA) diluted 
1:600 in 3% BSA was incubated ON at 4°C, followed by 
incubation with an anti-mouse IgG-Alexa 546 secondary 
antibody (1:2000) for 1 h at RT (Invitrogen-Thermo 
Fisher Scientific, Waltham, MA, USA). Cell nuclei were 
counter-stained with DAPI. The coverslips were mounted 
with Mowiol 4-88 (Calbiochem, Darmstadt, Germany). 
Olympus Fluoview FV 1000 confocal microscope with 
a UPLSAPO 60× 1.2 NA water immersion objective 
and a 2x digital zoom was employed. Excitation and 
emission filters were as follows: excitation DAPI, 405 
nm; emission DAPI, BP: 430–470 nm; excitation Alexa 
fluor 555, 543 nm; emission Alexa fluor 555, BP: 560– 
620 nm. We always used the sequential mode for image 
acquisition. All the quantitative microscopy measurements 
were performed in individual cells (13-76 cells for each 
treatment or condition). Confocal microscope images were 
processed with FIJI (https://fiji.sc). Channel backgrounds 
(mean of empty region) were subtracted. Segmentation 
of the nuclear compartment was performed for each 
cell using the DAPI signal. With this mask the nuclear 
β-Catenin signal was defined as the product of the DAPI 
mask and total β-Catenin signal. To calculate the nuclear 
fluorescence intensity for each cell, automatic recognition 
of the nuclei was performed to the previous segmented 
image using the Analyze Particles plug-in of FIJI. We 
evaluated the correct recognition of each nucleus visually.
Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded MCF-7-sh 
scramble, MCF-7-sh3 C2, MDA-MB231-vector and 
MDA-MB231-GPC3x2 tumors were cut at a thickness 
of 5 mm. Dewaxed sections in 0.01 M citrate buffer 
(pH 6.0) were heated at 90°C for 6 min. Endogenous 
peroxidase activity was blocked with 0.3% hydrogen 
peroxide in distilled water for 30 min, and non-specific 
immunoglobulin binding was blocked by incubation 
with 10% normal serum, during 60 min. Sections were 
incubated ON at 4°C with the primary antibody for 
E-Cadherin (1:50, BD Bioscience, San Jose, CA, USA) 
or ZEB1 (1:50, Santa Cruz Biotechnology, Dallas, TX, 
USA). Sections were rinsed and incubated for 30 min 
with universal secondary antibodies (1:15, Universal kit, 
Vector Laboratories, Burlingame-CA-USA). Slides were 
revealed by employing the Vectastain ABC Universal 
kit (Vector Laboratories, Burlingame-CA-USA) and the 
3,3′-diaminobenzidine chromogen (7%) plus 3% H2O2 in 
PBS and counterstained with Meyer’s hematoxylin.
All series included negative controls where the 
primary antibody was omitted. For analysis, images of 
multiple fields were captured. These images were then 
exported to FIJI (https://fiji.sc), the background subtracted 
and the Color De convolution plug-in applied according 
to the hematoxylin/DAB setting (H DAB) to provide two 
separate images representing the counter-staining and 
DAB immunostaining [50]. This DAB-specific image 
was then standardized to threshold, and the percentage of 
area occupied by the identified positive staining calculated 
for tumor using standard algorithms in FIJI. T student test 
(2-tailed) was used to evaluate the proportion expressing 
ZEB1 or E-Cadherin protein in MCF-7-sh scramble vs. 
–sh3 C2 and MDA-MB231-vector vs. –GPC3x2 tumors.
Silencing of GPC3 gene in MCF-7 cell line
To inhibit GPC3 expression, MCF-7 cells were 
transfected employing Fugene (Roche, Indianapolis, IN, 
USA), with the commercial plasmid pGPHI/GFP/Neo 
coding three shRNA-GPC3 different sequences (named 
sh1, sh2 and sh3), one shRNA-scramble (negative control) 
and one shRNA-GAPDH (positive control) (GenePharma 
Co., Shanghai, China) (Table 4). The selection was carried 
out with 400 μg/ml of G418 (Gibco LifeTechnologies, 
Carlsbad, CA, USA). We cloned the MC-F-7 transfected 
cells by limiting dilution. We selected MCF-7-sh3 GPC3 
bulk (named MCF7-sh3), MCF-7-sh3 GPC3 clone 2 
(named MCF-7-sh3 C2) and MCF-7-sh scramble bulk 
(named MCF-7-sh-scramble) sublines for studies.
Overexpression of GPC3 gene in MDA-MB231 
cell line
To overexpress GPC3, MDA-MB231 cells were 
infected with a lentivirus containing the pLV-GPC3-GFP 
or pLV-GFP (negative control) vector. Virus packaging 
was performed in 293-T cells after co-transfection of 
the target plasmid using Fugene (Roche, Indianapolis, 
IN, USA). Condition media was used for virus titration 
(pLV-GFP: 1.8 x 107 cfu/ml, pLV-GPC3-GFP: 2 x 106 cfu/
ml) 48 h post-transfection. MDA-MB231 cells (1 x 105) 
were infected, once or twice, with the filtered lentivirus 
and 2 mg/ml polybrene (Sigma-Aldrich, Saint Luis, MO, 
USA). Transduced cells were grown for 15 days with 
complete medium plus 10% FCS containing 400 μg/ml of 
G418 (Gibco LifeTechnologies, Carlsbad, CA, USA). The 
selected colonies were isolated and expanded.
We obtained the following sublines: MDA-MB231-
GPC3x1 (infected once with GPC3), MDA-MB231-
GPC3x2 (infected twice with GPC3), and MDA-MB231-
vector (infected with the empty vector).
Overexpression of ZEB1 in MDA-MB231-GPC3 
cells
To overexpress ZEB1, 5 x 105 MDA-MB231-
GPC3 cells were transfected by lipofection employing 
Lipofectamine 2000 (Gibco LifeTechnologies, Carlsbad, 
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CA, USA), with 3 μg of empty vector (pCDNAI/Amp) 
or ZEB1 expression vector (pCDNAI/ZEB1) [51]. Total 
extracts were used for immunoblots with anti ZEB1and 




800 monodispersed cells per well were seeded 
on 6-multiwell plates (Corning, Corning, NY, USA) in 
medium plus 10% FCS. Medium was changed every 
72 h. After 7 days, plates were washed, fixed with 5% 
acetic acid in methanol and stained with crystal violet. 
The number of colonies (>10 cells) was counted under 
inverted microscope. Clonogenic capacity was defined 
as the percentage of cells able to grow as colonies under 
these conditions. The assay was performed in triplicate.
Anchorage-independent growth
To study if the genetically modified cells are able 
to form spheroids, 20,000 cells/well (pre-incubated or 
not for 1 h with 200 μg/ml of anti E-Cadherin polyclonal 
antibody, H-108 sc-7870 Santa Cruz Biotechnology, 
Dallas, TX, USA), or IgG (400 μg/ml as isotype control) 
were seeded in wells coated with 1.5% agar (Gibco 
LifeTechnologies, Carlsbad, CA, USA). After 7 days 
growing in suspension with medium plus 10% FCS (or 
48 h for E-Cadherin antibody incubation), the spheroids 
were evaluated under inverted phase contrast microscope 
(Nikon, Eclipse TE2000-S). The experiment was done in 
triplicate.
Cell viability, death and apoptosis
Subconfluent monolayers were starved for 72 h. 
We performed Trypan blue exclusion assay to quantify 
viability (expressed as the percentage of living cells in 
relation to initially seeded cells). In addition, starved 
cells growing on coverslips were stained with 5 μg/ml of 
Höechst 33342 (Sigma-Aldrich, Saint Luis, MO, USA) 
and 5 mg/ml of propidium iodide (PI), for 15 min at 37°C. 
The percentage of cell death was calculated as the ratio 
of PI positive cells in relation to total cells stained with 
Höechst 33342. This relation was calculated in 10 random 
fields / coverslip. The experiment was done in triplicate.
Serum deprived MCF-7 sublines (72, 96, 120 
and 144 h) as well as serum deprived MDA-MB231 
sublines (18, 24, 48 and 72 h) were stained with 10 mg/ml 
acridine orange and 10 mg/ml ethidium bromide to assess 
apoptosis. Visualization was performed in a fluorescence 
microscope with 480 nm emissions (Nikon, Eclipse E400). 
Orange dyed cells were classified as apoptotic when they 
showed nuclear fragmentation (apoptotic bodies). The 
experiment was done in triplicate.
Cell migration
We performed a wound healing assay as described 
[28]. Briefly, cells were seeded in a 6-well plate and 
grown until confluence. Parallel wounds of about 400 
μm width were created by scraping with a pipette tip. To 
assess the ability of the cells to migrate into the wound 
area, each wound was photographed in three random 
microscopic fields, and the initial area was measured 
using the Image-Pro Plus 6.0 program. After 17 h, 
the same fields were photographed and the migratory 
Table 4: Sequences of primers used to qRT-PCR reactions
Name Target sequence
GPC3 F: 5’-GACGCCACCTGTCACCAAGT-3’R: 5’-AAACTCCCGTGCCAGGATC-3’
E-Cadherin F: 5’-GGTGCTCTTCCAGGAACCTC-3’R: 5’-GGAAACTCTCTCGGTCCAGC-3’
N-Cadherin F: 5’-GTACAGTGTAACTGGGCCAGG-3’R: 5’-GATCCAAGTCCAGCTGCCACTG-3’
Vimentin F: 5’-CCAAACTTTTCCTCCCTGAACC-3’R: 5’-GTGATGCTGAGAAGTTTCGTTGA-3’
SNAIL2 (SLUG) F: 5’-TCGGACCCACACATTACCTTG-3’R: 5’-TTCTCCCCCGTGTGAGTTCTA-3’
SNAIL1 F: 5’-CCAGTGCCTCGACCACTATG-3’R: 5’-CTGCTGGAAGGTAAACTCTGGA-3’
ZEB1 F: 5’-TGCACTGAGTGTGGAAAAAGC-3’R: 5’-TTGCAGTTTGGGCATTCATA-3’
GAPDH F: 5’-ACCCACTCCTCCACCTTTGA-3’R: 5’-ACGAATTTGGCTACAGCAACAG-3’
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capacity was calculated as the difference of the cell-
free area in each field. Experiments were carried out in 
triplicate.
In vivo tumor xenograft model
All experiments were carried out using 2-month-
old virgin female congenitally athymic nude mice (nu/
nu) (25 g each) obtained from the Animal Care Area of 
the UNLP (La Plata National University, BA, Argentina). 
Experiments have been conducted in accordance with 
the ethical standards and according to national and 
international guidelines (NIH guide for the Care and 
Use of Laboratory Animals) and were approved by the 
Institutional Ethical Committee, Institute of Oncology 
“Ángel H. Roffo”, University of Buenos Aires (CD Res. 
2012/11).
Non-anesthetized mice (from 5 to 10 animals / 
experimental group) were inoculated subcutaneously (s.c.) 
in the right flank with 7.5 x 106 MCF-7 (-sh scramble 
and -sh3 C2) or with 7 x 106 MDA-MB231 (-vector 
and -GPC3x2) cells in 0.2 ml serum-free RPMI 1640 
medium. MCF-7 cells-bearing mice received an estrogen 
supplementation with s.c. pellets of 0.5 mg 17-β-estradiol, 
one week before inoculation. The two largest perpendicular 
diameters were recorded twice a week to evaluate tumor 
growth, and the volume was calculated. We did growth 
curves for each experimental group, from which we 
obtained the tumor growth rate (expressed as mm3/day).
Three month post-inoculation, mice were sacrificed 
and their tumors were dissected, fixed with 10% formalin 
and embedded in paraffin. 5 μm sections were stained 
with hematoxylin and eosin for histopathology. For 
invasiveness behavior analysis, macroscopic examination 
and histopathological study of serial sections of s.c. tumors 
were performed. Tumors were classified as invasive when 
cells migrated through s.c. skeletal muscle layer and 
reached the dermis.
To investigate the presence of spontaneous 
metastases, lungs were removed and fixed in Bouin's 
solution. Lungs were macroscopic and histologically 
examined. Two serial section separated 100 μm were 
selected to score for parenchymatous nodules and 
micrometastasis/metastasis tumor foci under a high-power 
microscope. Liver, kidney and spleen were also examined 
for the presence of metastatic nodules. Three independent 
experiments were performed.
Statistical analysis
Data were presented as mean values ± standard 
deviation (SD), and statistical analyses were performed 
using Graph Pad InStat 3.0. The multiple comparisons of 
data were conducted by one way ANOVA test and Tuckey 
o Dunnett post-tests. Values of p<0.05 were considered 
statistically significant.
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